Early 18ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: A children's oncology group report

Peter D. Cole, Kathleen M. McCarten, Richard A. Drachtman, Pedro De Alarcon, Lu Chen, Tanya M. Trippett, Cindy L. Schwartz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.

Original languageEnglish (US)
Pages (from-to)650-657
Number of pages8
JournalPediatric Hematology and Oncology
Volume27
Issue number8
DOIs
StatePublished - Oct 18 2010
Externally publishedYes

Fingerprint

gemcitabine
Hodgkin Disease
Positron-Emission Tomography
Electrons
Survival
Therapeutics
Tomography
vinorelbine

Keywords

  • Gemcitabine
  • Hodgkin disease
  • Phase 2 trial
  • Positron emission tomography
  • Treatment response
  • Vinorelbine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Early 18ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease : A children's oncology group report. / Cole, Peter D.; McCarten, Kathleen M.; Drachtman, Richard A.; Alarcon, Pedro De; Chen, Lu; Trippett, Tanya M.; Schwartz, Cindy L.

In: Pediatric Hematology and Oncology, Vol. 27, No. 8, 18.10.2010, p. 650-657.

Research output: Contribution to journalArticle

Cole, Peter D. ; McCarten, Kathleen M. ; Drachtman, Richard A. ; Alarcon, Pedro De ; Chen, Lu ; Trippett, Tanya M. ; Schwartz, Cindy L. / Early 18ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease : A children's oncology group report. In: Pediatric Hematology and Oncology. 2010 ; Vol. 27, No. 8. pp. 650-657.
@article{4c577b03bea54451a54bde61d1b799d6,
title = "Early 18ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: A children's oncology group report",
abstract = "The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.",
keywords = "Gemcitabine, Hodgkin disease, Phase 2 trial, Positron emission tomography, Treatment response, Vinorelbine",
author = "Cole, {Peter D.} and McCarten, {Kathleen M.} and Drachtman, {Richard A.} and Alarcon, {Pedro De} and Lu Chen and Trippett, {Tanya M.} and Schwartz, {Cindy L.}",
year = "2010",
month = "10",
day = "18",
doi = "10.3109/08880018.2010.504250",
language = "English (US)",
volume = "27",
pages = "650--657",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Early 18ffluorodeoxyglucose positron emission tomographybased response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease

T2 - A children's oncology group report

AU - Cole, Peter D.

AU - McCarten, Kathleen M.

AU - Drachtman, Richard A.

AU - Alarcon, Pedro De

AU - Chen, Lu

AU - Trippett, Tanya M.

AU - Schwartz, Cindy L.

PY - 2010/10/18

Y1 - 2010/10/18

N2 - The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.

AB - The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.

KW - Gemcitabine

KW - Hodgkin disease

KW - Phase 2 trial

KW - Positron emission tomography

KW - Treatment response

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=77958051538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958051538&partnerID=8YFLogxK

U2 - 10.3109/08880018.2010.504250

DO - 10.3109/08880018.2010.504250

M3 - Article

C2 - 20863157

AN - SCOPUS:77958051538

VL - 27

SP - 650

EP - 657

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 8

ER -